<code id='16222134C6'></code><style id='16222134C6'></style>
    • <acronym id='16222134C6'></acronym>
      <center id='16222134C6'><center id='16222134C6'><tfoot id='16222134C6'></tfoot></center><abbr id='16222134C6'><dir id='16222134C6'><tfoot id='16222134C6'></tfoot><noframes id='16222134C6'>

    • <optgroup id='16222134C6'><strike id='16222134C6'><sup id='16222134C6'></sup></strike><code id='16222134C6'></code></optgroup>
        1. <b id='16222134C6'><label id='16222134C6'><select id='16222134C6'><dt id='16222134C6'><span id='16222134C6'></span></dt></select></label></b><u id='16222134C6'></u>
          <i id='16222134C6'><strike id='16222134C6'><tt id='16222134C6'><pre id='16222134C6'></pre></tt></strike></i>

          Home / comprehensive / Wikipedia

          Wikipedia


          Wikipedia

          author:explore    Page View:5
          David L. Ryan/Boston Globe

          A team of high-powered scientists and billionaire investors said Friday that they’re launching a biomedical institute in Cambridge’s Kendall Square with $500 million in private funding with the aim of shortening the path from research breakthroughs to life-saving medicines.

          The institute, called Arena BioWorks, will put drug discovery and company creation under one roof, upending the traditional model where academic research and venture-backed drug development are separate.

          advertisement

          Backed by deep-pocketed investors including Steve Pagliuca, the former co-chair of Bain Capital and Celtics co-owner, and high-tech mogul Michael Dell, Arena has already lured top scientists from academic labs with lucrative compensation packages, but so far has publicly named only a few.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In